TITLE

Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment

AUTHOR(S)
Shaikh, Saeed A.
PUB. DATE
December 2007
SOURCE
Journal of the Canadian Chiropractic Association;Dec2007, Vol. 51 Issue 4, p249
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Ankylosing spondylitis (AS) is generally easy to diagnose when the characteristic findings of the "bamboo" spine and fused sacroiliac joints are present on radiographs. Unfortunately, these changes are usually seen late in the disease after tremendous suffering has been incurred by the patient. Diagnostic delay averages seven to ten years. Historically, once the diagnosis was made, the treatment options were often inadequate or poorly tolerated in many individuals. This condition most often starts in early adulthood when people are typically in the earlier stages of their careers, resulting in diminished workforce participation and decreased quality of life. If an individual has a family physician, this might be the first encounter with a healthcare provider. Quite often, the initial practitioner is sought at a public walk-in clinic or chiropractic office. In recent years, there have been two major developments in the management of AS that make earlier diagnosis possible and offer the hope of alleviating pain and preventing structural changes that result in loss of function. These developments include the use of magnetic resonance imaging (MRI) to visualize the inflammatory changes in the sacroiliac joint and the axial spine, and the demonstration that tumor necrosis factor (TNF) blocking agents are highly efficacious in reducing spinal inflammation and possibly in slowing radiographic progression. This review outlines diagnostic strategies that can help identify AS in its earlier stages. Special attention is focused on treatment advances, including the use of anti-TNF agents, and how these medications have been incorporated into clinical recommendations for daily use.
ACCESSION #
27746155

 

Related Articles

  • Ankylosing Spondylitis.  // Bulletin of the NYU Hospital for Joint Diseases;2010, Vol. 68 Issue 3, p171 

    No abstract available.

  • MRT-Untersuchungen bei axialer und peripherer Spondyloarthritis. Baraliakos, X.; Braun, J. // Zeitschrift für Rheumatologie;Jan2012, Vol. 71 Issue 1, p27 

    The diagnosis of ankylosing spondylitis (AS) is based on the modified New York criteria and therefore on defined structural changes in the sacroiliac joint as detected by conventional radiographs. However, x-rays are not able to detect early stages of the disease in which inflammation...

  • Loss of anterior concavity of the first sacrum can predict spinal involvement in ankylosing spondylitis. Kim, Ji; Lee, Seunghun; Joo, Kyung; Song, Yoonah; Joo, Young; Kim, Tae-Hwan // Rheumatology International;Jan2016, Vol. 36 Issue 1, p161 

    In this study, we evaluated the frequency of squaring of the first sacrum (S1), defined as the loss of anterior concavity, in patients with ankylosing spondylitis (AS). We also determined the interobserver reliability in the assessment of S1 squaring and the relationships of S1 squaring with MRI...

  • Frühtherapie bei axialer Spondyloarthritis und Relevanz der radiologischen Progression. Song, I.H.; Sieper, J. // Zeitschrift für Rheumatologie;Jan2012, Vol. 71 Issue 1, p38 

    In recent years great achievements have been made in terms of early diagnosis of axial spondyloarthritis (SpA). In addition new classification criteria have been established. An early diagnosis offers the possibility for effective early treatment. For the treatment of axial SpA according to the...

  • Demyelination during anti-TNFα therapy for ankylosing spondylitis. Mercieca, Cecilia; Vella, Norbert; Borg, Andrew // Modern Rheumatology (Springer Science & Business Media B.V.);Apr2012, Vol. 22 Issue 2, p303 

    A 34-year-old ankylosing spondylitis (AS) patient on etanercept for 30 months presented to neurologists with paresthesia of his hands and feet. Magnetic resonance imaging (MRI) scans showed multifocal hyperintense lesions. Symptoms did not improve on stopping the anti-tumor necrosis factor (TNF)...

  • Early Diagnosis of AS or Other SpA - From Clinical and Radiologic Viewpoint. Kumar, Ashok; Das, Chandan J. // Current Rheumatology Reviews;2009, Vol. 5 Issue 3, p169 

    Until a decade ago, treatment of ankylosing spondylitis (AS) used to be quite unsatisfactory. However, the advent of TNF blockers has brought about a dramatic change in clinical approach to this disease. The long diagnostic delay- typically 7 to 10 years in the past- is no longer considered...

  • Discovertebral (Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography. de Vries, Mirjam K.; van Drumpt, Anne S.; van Royen, Barend J.; van Denderen, J. Christiaan; Manoliu, Radu A.; van der Horst-Bruinsma, Irene E. // Clinical Rheumatology;Dec2010, Vol. 29 Issue 12, p1433 

    The objective of this study is to investigate the prevalence of Andersson lesions (AL) in ankylosing spondylitis (AS) patients who will start anti-tumor necrosis factor (TNF) treatment. Radiographs and magnetic resonance imaging (MRI) of the spine were performed before therapy with anti-TNF. ALs...

  • Assessment of therapeutic response in ankylosing spondylitis patients undergoing anti-tumour necrosis factor therapy by whole-body magnetic resonance imaging. Karpitschka, Martina; Godau-Kellner, Patrizia; Kellner, Herbert; Horng, Annie; Theisen, Daniel; Glaser, Christian; Brandlhuber, Bernhard; Reiser, Maximilian; Weckbach, Sabine // European Radiology;Jul2013, Vol. 23 Issue 7, p1773 

    Objectives: Multifocal musculoskeletal inflammation is common in ankylosing spondylitis (AS) and is effectively treated by expensive anti-TNF (tumour necrosis factor) therapy. This study evaluated assessment of response by whole-body (WB) MRI compared with clinical assessment in AS patients...

  • Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Senabre-Gallego, José Miguel; Santos-Ramírez, Carlos; Santos-Soler, Gregorio; Salas-Heredia, Esteban; Sánchez-Barrioluengo, Mabel; Barber, Xavier; Rosas, José // Patient Preference & Adherence;2013, Vol. 7, p961 

    To date, anti-tumor necrosis factor alfa (anti-TNF-Ï°) therapy is the only alternative to nonsteroidal anti-inflammatory drugs for the treatment of ankylosing spondylitis. Etanercept is a soluble TNF receptor, with a mode of action and pharmacokinetics different to those of antibodies and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics